95538-32-2

Usage

Explanation

The compound consists of 9 carbon atoms, 6 hydrogen atoms, 1 bromine atom, 1 chlorine atom, and 1 nitrogen atom.

Explanation

The Chemical Abstracts Service (CAS) registry number is a unique identifier for this specific chemical compound.

Explanation

1H-Indole-2-carbonyl chloride,5-Bromo is derived from the indole structure, which is a core structure found in various natural and synthetic compounds.

Explanation

1H-INDOLE-2-CARBONYL CHLORIDE,5-BROMO is frequently used as a building block or intermediate in the synthesis of more complex organic molecules, particularly in the fields of pharmaceuticals and agrochemicals.

Explanation

The compound appears as a white to off-white powdery solid.

Explanation

The compound does not readily react or degrade when stored or handled under standard environmental conditions.

Explanation

1H-Indole-2-carbonyl chloride,5-Bromo serves as a valuable intermediate in the synthesis of various pharmaceuticals and agrochemicals due to its functional groups and substituents.

Explanation

The presence of a bromine atom in the compound makes it a valuable building block for the development of new drugs and bioactive compounds, as bromine can influence the compound's properties and reactivity.

Explanation

It is important to handle 1H-Indole-2-carbonyl chloride,5-Bromo with care, as it may pose risks to human health and the environment if not properly managed.

Physical appearance

White to off-white powder

Stability

Stable under normal conditions

Upstream product

• 7254-19-5 5-bromo-2-indolecarboxylic acid 

Downstream Products

• 1278517-86-4 1-(5-phenyl-1H-indol-2-yl)-2-(pyridin-3-yl)-ethan-1-one 
• 103343-97-1 1,3-Dihydro-3-(RS)-(5-Bromoindole-2-carbonylamino)-5-(2-fluorophenyl)-2H-1,4-benzodiazepin-2-one 

Relevant academic research and scientific papers

Structure-based discovery of 1H-indole-2-carboxamide derivatives as potent ASK1 inhibitors for potential treatment of ulcerative colitis

Apoptosis signal-regulating kinase 1 (ASK1), a member of the mitogen-activated protein kinase (MAPK) family, is implicated in many human diseases. Here, we describe the structural optimization of hit compound 7 and conduct further structure-activity relationship (SAR) studies that result in the development of compound 19 with a novel indole-2-carboxamide hinge scaffold. Compound 19 displays potent anti-ASK1 kinase activity and stronger inhibitory effect on ASK1 in AP1-HEK293 cells than previously described ASK1 inhibitor GS-4997. Besides improved in vitro activity, compound 19 also exhibits an appropriate in vivo PK profile. In a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis (UC), compound 19 shows significant anti-UC efficacy and markedly attenuates DSS-induced body weight loss, colonic shortening, elevation in disease activity index (DAI) and inflammatory cell infiltration in colon tissues. Mechanistically, compound 19 represses the phosphorylation of ASK1-p38/JNK signaling pathways and suppresses the overexpression of inflammatory cytokines. Together, these findings suggest that ASK1 inhibitors can potentially be used as a therapeutic strategy for UC.

Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors

Indoleamine 2,3-dioxygenase (IDO) is a heme dioxygenase which has been shown to be involved in the pathological immune escape of diseases such as cancer. The synthesis and structure-activity relationships (SAR) of a novel series of IDO inhibitors based on the indol-2-yl ethanone scaffold is described. In vitro and in vivo biological activities have been evaluated, leading to compounds with IC50 values in the micromolar range in both tests. Introduction of small substituents in the 5- and 6-positions of the indole ring, indole N-methylation and variations of the aromatic side chain are all well tolerated. An iron coordinating group on the linker is a prerequisite for biological activity, thus corroborating the virtual screening results.

INDOLES USEFUL IN THE TREATMENT OF INFLAMATION

There is provided compounds of formula (I), Wherein T, Y, X1 , R1, R2, R3, R4 and R5 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.